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Abstract
Alphavirus replicon particles induce strong antibody and CD8+ T cell responses to expressed
antigens in numerous experimental systems. We have recently demonstrated that Venezuelan
equine encephalitis virus replicon particles (VRP) possess adjuvant activity for systemic and
mucosal antibody responses. In this report, we demonstrate that VRP induced an increased and
balanced serum IgG subtype response to co-delivered antigen, with simultaneous induction of
antigen-specific IgG1 and IgG2a antibodies, and increased both systemic and mucosal antigen-
specific CD8+ T cell responses, as measured by an IFN-γ ELISPOT assay. Additionally, VRP
further increased antigen-specific T cell immunity in an additive fashion following co-delivery
with the TLR ligand, CpG DNA. VRP infection led to recruitment of CD8+ T cells into the
mucosal compartment, possibly utilizing the mucosal homing receptor, as this integrin was
upregulated on CD8+ T cells in the draining lymph node of VRP-infected animals, where VRP-
infected dendritic cells reside. This newly recognized ability of VRP to mediate increased T cell
response towards co-delivered antigen provides the potential to both define the molecular basis of
alphavirus-induced immunity, and improve alphavirus-based vaccines.
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1. INTRODUCTION
To date, vaccination is the most effective strategy for protection against morbidity and
mortality associated with infectious agents [1]. The exact immunological mechanisms which
serve as the critical protective factor/s vary widely depending upon the specific pathogen
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[2]. Likewise, the nature and makeup of the particular vaccine shapes the qualitative and
quantitative aspects of the host immune response. In general terms, protection is
traditionally associated with either the induction of a neutralizing antibody response, the
induction of a cell mediated immune response, or both [2]. There are a number of examples
in which the immune correlates of protection have been identified (reviewed in [2]);
however, correlates have not been defined for important pathogens, such as human
immunodeficiency virus (HIV) [3, 4]. Therefore, vaccination regimens capable of
stimulating both a broadly active antibody response and cell mediated immunity represent
an opportunity to interdict in the spread of such diseases.
Immunogen delivery systems based upon the alphaviruses have proven to be efficient
inducers of both neutralizing antibody responses and cell mediated immune responses to
multiple antigens, including HIV antigens, expressed from the viral genome (reviewed in
[5–11]). Alphavirus vectors derived from Sindbis virus, Semliki forest virus (SFV), and
Venezuelan equine encephalitis virus (VEE) have generated the most promising results to
date and all three of these systems are actively under investigation as candidate HIV vaccine
vectors in several laboratories. Replicon particles harbor a modified genome; the viral non-
structural genes, which encode the proteins required to replicate the genomic RNA, are
expressed from the 5′ two thirds of the genome, while the viral 26S subgenomic promoter
catalyzes the transcription of the remainder of the genome into a subgenomic mRNA [12].
The genome of replication-competent virus contains the viral structural genes, the capsid
and E1 and E2 glycoprotein genes, expressed from the 26S promoter. This structural gene
cassette has been replaced with a cloned antigen of interest in the vaccine replicon
constructs [13]. In order to package these defective replicon genomes into replicon particles,
the replicon RNA is co-electroporated into permissive cells with two helper RNAs which
together drive the expression of the structural components in trans. However only the
replicon RNA is incorporated into replicon particles, as the viral-specific packaging signal is
deleted from the helper constructs [14]. VEE replicon particles (VRP) are currently under
development as an HIV vaccine platform in part for the ability to stimulate cell-mediated
immune responses directed against expressed antigens [15–19].
CD8+ T cells are activated following interaction with antigen presenting cells (APCs) that
present on their surface peptide fragments in the context of major histocompatibility
complex I (MHC I), along with co-stimulatory molecules [20]. Two pathways of antigen
loading into MHC class I molecules have been described. In the endogenous pathway,
peptide fragments derived from cytosolic proteins are transported into the endoplasmic
reticulum (ER) via the transporter associated with antigen processing (TAP) molecule [21]
and then transported to the cell surface for presentation to cognate CD8+ T cells [22]. In
addition to the endogenous pathway, a separate pathway of exogenous antigen loading,
termed cross-presentation, also has been identified, which directs exogenous antigens into
the class I pathway in a TAP-independent manner, providing a means for the activation of
CD8+ T cell responses against pathogens which do not directly infect APCs [23, 24].
Some infectious agents directly infect APCs, which contain a number of cellular pathogen
recognition molecules. For example, toll-like receptors (TLRs) are pattern recognition
receptors which recognize conserved motifs, or pathogen associated molecular patterns
(PAMPs) [25] and play a critical role in shaping both innate and adaptive immune responses
[26, 27]. Delivery of numerous TLR ligands promotes pro-inflammatory cytokine secretion
and cross-priming of CD8+ T cells [28].
We have recently identified a novel activity of VRP, that they act as adjuvants for both
systemic and mucosal antibody responses to antigens that are simply mixed with VRP
encoding either an irrelevant transgene or no transgene at all [29]; however, CD8+ T cell
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adjuvant effects were not evaluated in those studies. When VRP are utilized as expression
vectors, all VRP-infected cells also contain the expressed antigen. Following delivery of
antigen mixed with VRP adjuvants, both VRP and antigen are likely to be sequestered to the
same draining lymph node. However, antigen may or may not be taken up by the same
dendritic cells (DCs) that are targets of VRP infection [30]. Therefore, it is theoretically
possible that co-delivered antigen could be processed in a very different manner than
antigens expressed from the VRP genome, leading to a discinct effect on CD8+ T cell
activation.
In this report we have assessed the ability of VRP, either alone or in combination with a
representative TLR ligand (CpG DNA), to activate cell-mediated immunity to a co-delivered
antigen. VRP infection produced an adjuvant effect, promoting increased systemic and
mucosal CD8+ T cell responses to co-delivered protein antigen, and an additive increase in
the presence of CpG DNA, as measured by IFN-γ secretion. Interestingly, nonmucosal VRP
delivery resulted in a recruitment of CD8+ T cells into the mucosal compartment, as well as
an increase in expression of the mucosal homing receptor on CD8+ T cells in the peripheral
draining lymph node (DLN). Taken together these results suggest that VRP promote not
only increased antibody responses [29], but also T cell responses to co-delivered antigens in
both the systemic and mucosal compartments.
2. MATERIALS AND METHODS
2.1. VEE replicon particles
The VRP utilized in this report were prepared and packaged as previously described [14,
31]. Briefly, in vitro-transcribed replicon RNA, along with two defective helper RNAs,
which express the viral structural genes in trans, were co-electroporated into BHK-21 cells.
Only the replicon RNA was packaged into particles as the viral-specific packaging signal is
absent from the helper RNAs. In this study, we have utilized a replicon which lacks a
functional transgene downstream of the 26S promoter (null VRP) [29]. All replicon particles
were packaged in the wild-type VEE (V3000) envelope [32].
2.2. Animals and immunizations
Seven-to-10-week-old female BALB/c or C57BL/6 mice were immunized in a 0.01 ml
volume in the rear footpad(s) as previously described [29]. Animals were immunized at
week 0 and week 4 with antigen alone or antigen co-inoculated with either VRP and/or CpG
DNA as an adjuvant. Chicken egg albumin (OVA) was purchased from Sigma and CpG
DNA (ODN 1826) was purchased from Invivogen. Diluent consisted of low endotoxin,
filter-sterilized PBS. For peptide immunization experiments, animals were immunized in
both rear footpads in a 0.02 ml volume with the class I-restricted OVA peptide (SIINFEKL,
New England Peptide) at weeks 0, 4, and 8.
2.3. Serum collection
Collection of serum from immunized animals was performed as previously described [29].
Blood was harvested either from the tail vein, following cardiac puncture, or from the
submandibular plexus from individual animals and sera collected following centrifugation in
microtainer serum separator tubes (Becton Dickinson).
2.4. Cell preparation and flow cytometric analysis
For preparation of single cell suspension from the DLN, DLNs were harvested from
immunized animals and each lymph node was disrupted with a razor blade and a hemostat,
and single cell suspensions were created by agitating each lymph node in complete RPMI
medium [RPMI medium 1640 containing 10% (vol/vol) FBS, 2 mM L-glutamine, 50 μg/ml
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gentamicin, 100 units/ml penicillin, 100 μg/ml streptomycin, and 15 mM Hepes] containing
2.5 mg/ml Collagenase A (Roche Applied Science) and 17 μg/ml DNase I (Roche Applied
Science) for 30 minutes at 37°C. Single cell suspensions were then stained with antibodies
directed against CD3, CD19, CD45 (B220), CD11c, CD11b (all purchased from
ebioscience) as well as α4β7 integrin (LPAM-1, clone DATK32, BD Pharmingen) and
CCR9 (R&D Systems) and examined on a Becton Dickinson Facscaliber Flow cytometer
and analyzed using Cellquest software.
For preparation of single cell suspensions from the spleen, whole spleens were disrupted
between frosted glass slides, and red blood cells were lysed following addition of
ammonium chloride buffer. Cells were pooled from two animals, washed and banded on a
Lympholyte-M density gradient (Accurate), and counted as described [29].
Nasal lymphocytes were also prepared as previously described [29]. Briefly, nasal tissue
was physically and enzymatically disrupted by incubation at 37°C for 2 hrs in a 50 ml
Erlenmeyer flask in complete R-10 containing 2.5mg/ml Collagenase A (Roche), 17 μg/ml
DNase I (Roche) and glass beads. Following digestion, cells were filtered through a 40 μm
cell strainer (BD Falcon), washed, resuspended in 44% Percoll (Amersham) and layered on
Lympholyte-M. Banded cells were harvested, washed, and counted. Cells were pooled from
two animals and typical yields were approximately 2.5×105 to 1×106 cells per animal.
2.5. Enzyme Linked Immunosorbant Assay (ELISA)
ELISAs for OVA-specific antibodies were performed on serum as previously described
[29]. Briefly, an OVA solution (1 mg/ml in PBS) was incubated in 96-well plates (Costar)
overnight at 4°C and subsequently blocked overnight with blocking solution [PBS 1x
Sigmablock (Sigma)] at RT. Plates were next incubated at room temperature (RT) overnight
with 2-fold serial dilutions of individual samples. Plates were washed and incubated for 1 hr
with horseradish peroxidase-conjugated secondary goat anti-mouse IgG1 or IgG2a chain-
specific antibodies (Southern Biotechnology Associates or Sigma). Finally, plates were
again washed, and developed following delivery of O-phenylenediamine dihydrochloride
substrate. Antibody endpoint titers are reported as the reciprocal of the highest dilution that
resulted in an OD450 ≥0.2. Data are presented as the geometric mean ± standard error of the
mean (SEM).
2.6. IFN-γ enzyme-linked immunospot assay (ELISPOT)
An IFN-γ ELISPOT assay was employed to quantitate OVA-specific IFN-γ-secreting cells,
present in both the spleen and nasal epithelium of immunized mice. Nitrocellulose
membrane plates (96 well; Millipore) were incubated with 5 μg/ml of an anti-IFN-γ
antibody (AN18, Mabtech) in sodium bicarbonate buffer (pH 9.6) overnight at 4°C. Plates
were then washed and blocked for 2 hrs with complete R-10 (10% fetal bovine serum) at
37°C. Single cell suspensions in R-10 (1×105 to 2.5×105 cells per well) from either spleen or
nasal epithelium were then added to plates in duplicate and incubated in the presence and
absence of the class I-restricted OVA peptide (SIINFEKL, New England Peptide) for 24 hrs.
Cells were removed from plates, plates were washed, a biotinylated anti-IFN-γ antibody
(R4-6A2, 1 μg/ml, Mabtech) was added to the plates, and the plates were incubated for 18
hours at 4°C. Membranes were again washed, incubated with a streptavidin-alkaline
phosphotase conjugate for 2 hrs at RT. Plates were washed, and spots were developed
following addition of BCIP/NBT substrate. Spots were enumerated with a computerized
ELISPOT plate reader (Immunospot). Assay background values were obtained following
incubation with either no peptide or an irrelevant peptide and were subtracted from values
obtained with the OVA peptide. Data are normalized to the number of antigen-specific IFN-
γ-secreting-cells per 106 cells.
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2.7. Intracellular cytokine staining
Single cell suspensions were prepared from spleen and nasal epithelium as described above.
2×105 to 2×107 cells were incubated for 6–8 hours in media containing 10 μg/ml of
Brefeldin A alone, media containing Brefeldin A and 2 μg/ml of the class I-restricted OVA
peptide (SIINFEKL), 2 μg/ml of an irrelevant peptide, or 5 μg/ml conconavalin A. Cells
were then washed and stained with antibodies against cell surface markers (CD8, CD4,
CD3, etc) for 30 mins. Cells were washed, fixed and permeabilized (Bectin Dickinson
cytofix cytoperm), and stained with an antibody against IFN-γ (Mabtech). Cells were
washed and stored at 4°C prior to analysis by flow cytometry.
2.8. Pentamer staining
Single cell suspensions prepared from animals immunized with the class I OVA peptide
(SIINFEKL) were analyzed for the presence of OVA-specific cells via cell surface staining
with antibodies against CD3, CD8, and the Kb-restricted SIINFEKL pentamer (Proimmune)
according to manufacturer guidelines. Stained cells were examined on a Becton Dickinson
Facscaliber Flow cytometer and analyzed using Cellquest software. Data are reported as the
percentage of CD3+, CD8+ cells which also stain positive with the OVA pentamer. Values
are presented as geometric mean +/− SEM.
2.9. Statistical Analysis
Antibody titers and cytokine values were evaluated for statistically significant differences by
either the ANOVA or Mann-Whitney test (GraphPad INSTAT). Results are reported
without adjustment for multiple comparisons. A p value of ≤0.05 was considered significant.
3. RESULTS
3.1. VRP adjuvants promote a balanced Th1/Th2 antibody profile
We have previously demonstrated the ability of VRP to increase the systemic and mucosal
antibody response to co-delivered antigens (Thompson et al., In Press; [29]). Additionally,
both Th1 and Th2 cytokines were induced in the VRP-draining lymph node at early times
following VRP delivery (Thompson et al., In Press;[33]). Here we have further characterized
the antigen-specific serum IgG antibody profile for the presence of IgG1 and IgG2a
antibodies as an indirect measure of the Th1/Th2 cytokine profile following VRP
immunization. Groups of eight female Balb/c mice were immunized in the rear footpad at
week 0 and week 4 with OVA alone (10 μg), or OVA (10 μg) mixed with either null VRP
(1×105 IU) or CpG DNA (1 μg ). We have utilized footpad delivery here due to our
extensive experience using this route in VEE pathogenesis studies. Footpad infection targets
antigens to a single DLN and provides a tractable system to study the first infected cells and
the effects of VRP delivery on the immune inductive tissues [30]. Two weeks following the
second inoculation, sera were collected and analyzed for the presence of OVA-specific IgG
antibodies by ELISA. The OVA-specific total IgG results shown in Figure 1A were
previously reported in a different format in Thompson et al. [29], and are reprinted here for
clarity. As shown in Figure 1A, the inclusion of null VRP in the inoculum increased the
OVA-specific IgG antibody response by approximately 40-fold. As expected, delivery of
OVA plus CpG DNA as an adjuvant likewise induced an approximately 40-fold increase in
the systemic IgG antibody response. We next analyzed the same sera for the presence of
OVA-specific IgG1 and IgG2a antibodies by ELISA. Delivery of OVA alone resulted in a
strong OVA-specific IgG1 response relative to the IgG2a response, with an IgG1: IgG2a
ratio of >20 (Figure 1B). In contrast, inclusion of VRP as an adjuvant significantly increased
the OVA-specific IgG2a response, while simultaneously inducing an OVA-specific IgG1
antibody titer similar to that of antigen delivery alone. This resulted in a balanced IgG1:
IgG2a ratio of 0.8 (Figure 1B). A similarly balanced IgG1: IgG2a ratio was observed
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following delivery of OVA and CpG DNA (0.5). These results suggest that VRP co-delivery
significantly alters the systemic IgG subtype profile compared to delivery of antigen alone,
and results in a balanced antibody response with the production of both Th1 and Th2 IgG
antibodies [34, 35]. The antibody adjuvant data presented here and in Thompson et al. [29]
were derived from experiments performed in Balb/c mice; however, we have observed
significant antibody adjuvant activity in several mouse strains including Balb/c, C57BL/6,
and 129 Sv/Ev, suggesting that the VRP adjuvant effect is not dependent upon a specific
mouse genotype (Thompson J.M. and Johnston R.E., unpublished observations).
3.2. VRP adjuvants promote an increased cellular immune response to co-delivered
soluble antigen
To determine whether VRP possess the ability to stimulate CD8+ T cell responses to co-
delivered antigens, groups of eight female C57BL/6 mice were immunized in the rear
footpad at week 0 and week 4 with OVA alone (100 μg), or with OVA (100 μg) mixed with
null VRP (1×105 IU), CpG DNA (1 μg), or both null VRP (1×105 IU) and CpG DNA (1 μg)
simultaneously. Two weeks following the second immunization, animals were sacrificed
and single cell suspensions were prepared from the spleen, a characteristic systemic
lymphoid organ, and from the nasal epithelium, a characteristic mucosal tissue. Splenocytes
and nasal lymphocytes were evaluated for the presence of IFN-γ-secreting cells following
stimulation with the class I-restricted OVA peptide (SIINFEKL) in an IFN-γ ELISPOT
assay. As shown in Figure 2, delivery of OVA alone resulted in low, but detectable levels of
OVA-specific CD8+ T cell responses in both the spleen (Figure 2A) and the nasal
epithelium (Figure 2B). This response was increased approximately 12-fold in the spleen,
and 7-fold in the nasal epithelium when VRP were included as an adjuvant. CpG DNA also
demonstrated a significant adjuvant effect in the systemic and mucosal compartments. When
both VRP and CpG were combined as adjuvants, the OVA ELISPOT response was
increased further, compared to either VRP or CpG DNA alone. Taken together, these results
suggest that VRP as an adjuvant increases the CD8+ T cell response to soluble protein
antigen, and that combining VRP and CpG DNA provides an additive adjuvant effect.
3.3. VRP adjuvants promote an increased cellular immune response to co-delivered
peptide antigen
VRP may augment CD8+ T cell immunity at various stages in the T cell activation pathway,
both upstream and downstream of antigen processing. As a first step in characterizing the T
cell activation pathway in which VRP and CpG are active, the ability of VRP to augment
CD8+ T cell responses was examined under experimental conditions which do not require
antigen processing to individual peptides. Groups of eight female C57BL/6 mice were
immunized in the rear footpad at week 0 and week 4 with 20 μg OVA peptide (SIINFEKL)
alone followed by a third inoculation of 10 μg of peptide to maximize the CD8+ T cell
response induced by peptide antigen alone. In addition, mice were immunized with OVA
peptide in the same amounts, and on the same dosing schedule mixed with either null VRP
(1×105 IU), CpG DNA (1 μg), or both null VRP (1×105 IU) and CpG DNA (1 μg). Two
weeks following the third immunization, animals were sacrificed and single cell suspensions
were prepared from the spleen and nasal epithelium. Splenocytes were first examined for
IFN-γ secretion by ELISPOT. As shown in Figure 3A, delivery of OVA peptide alone failed
to induce significant numbers of OVA-specific IFN-γ-secreting cells in the spleen, as
measured by IFN-γ ELISPOT. However, when VRP were co-inoculated with OVA peptide,
OVA-specific IFN-γ-secreting cells were detectable in the spleen at approximately 10-fold
higher levels than present following delivery of peptide alone. A similar increase was also
observed following use of CpG as an adjuvant. Moreover, delivery of OVA peptide in the
presence of both VRP and CpG DNA resulted in a significantly stronger response than
delivery of either adjuvant alone (p<0.01). To further characterize the OVA-specific T cell
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response following peptide delivery, OVA-specific CD8+ T cells were evaluated by
SIINFEKL/MHC I pentamer analysis. Delivery of OVA peptide in the presence of both
VRP and CpG resulted in an increased proportion of OVA-specific CD8+ T cells in both the
spleen (Figure 3B) and nasal epithelium (Figure 3C) compared to delivery of OVA peptide
alone. However, delivery of OVA peptide in the presence of either VRP or CpG did not
result in a statistically significant increase in the proportion of OVA-specific CD8+ T cells
compared to delivery of OVA peptide alone. Taken together, these results suggest that VRP,
in combination with CpG DNA, increase the antigen-specific CD8+ T cell response to
peptide antigen.
3.4. Nonmucosal VRP delivery results in increased numbers of mucosal CD8+ T cells
In addition to the high dose (100 μg) OVA experiments presented in Figure 2, we also
employed an intracellular cytokine staining (ICS) assay for IFN-γ following low dose (10
μg) OVA administration in the presence/absence of a VRP adjuvant. Groups of eight female
C57BL/6 mice were immunized in the rear footpad at week 0 and week 4 with OVA alone
(10 μg), or with OVA (10 μg) mixed with null VRP (1×105 IU) and splenocytes and nasal
lymphocytes were evaluated for the presence of IFN-γ positive CD8+ T cells by ICS two
weeks following the booster immunization. In this model, IFN-γ+ CD8+ T cells were
essentially undetectable by ICS in the spleens of immunized animals regardless of the
presence of VRP in the inoculum (data not shown). IFN-γ+ CD8+ T cells were detectable in
the nasal epithelium of immunized animals; however, the presence of VRP in the inoculum
did not induce a statistically significant increase compared to delivery of OVA alone (Figure
4A).
We next evaluated whether VRP delivery affected the number of CD8+ T cells in the nasal
mucosa of immunized animals. Interestingly, inclusion of VRP in the inoculum resulted in
an approximately 5-fold increase in the proportion of viable CD8+ T cells in the nasal
epithelium (Figure 4B). This effect results in an increase in the absolute number of OVA-
specific CD8+ T cells in the nasal mucosa, even under conditions where the proportion of
OVA-specific IFN-γ-secreting cells was not increased (Figure 4C). The proportion of CD8+
T cells in the spleen was unaffected by VRP delivery (data not shown), suggesting that
CD8+ T cells may be recruited specifically into the mucosal compartment when VRP are
utilized as adjuvants.
3.5. Nonmucosal VRP delivery upregulates the mucosal homing receptor on CD8+ T cells
in the draining lymph node
As a first step in characterizing the recruitment of T cells to the mucosal surface following
VRP delivery, levels of two important mucosal homing molecules, the α4β7 integrin and
CCR9 [36], were evaluated on T cells present in the DLN. Groups of female Balb/c mice
were immunized in the rear footpads with OVA (10 μg) in the presence and/or absence of
null VRP (1×105 IU) at week 0 and week 4 and DLNs were harvested at day 1 and day 3
following the second inoculation. Single cell suspensions were created by collagenase
digestion and cells were stained with antibodies against CD3, CD4, CD8, CCR9, and the
α4β7 integrin (LPAM-1). At day 1 post boost, both CD4+ T cells and CD8+ T cells were
present in the DLN of immunized animals; however, neither CCR9 nor α4β7 integrin was
upregulated by the inclusion of VRP in the inoculum (data not shown). At day 3 post boost,
CCR9 levels were not increased on either CD4+ T cells or CD8+ T cells present in the DLN
(Figure 5). In contrast, the number of DLN CD8+ T cells with upregulated α4β7 integrin
expression was increased following OVA plus VRP delivery, compared to delivery of OVA
alone at day 3. The proportion of CD4+ T cells with increased α4β7 integrin expression in
the DLN were unaffected by VRP at the same timepoint. Together, these results suggest that
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mucosal homing molecule expression on CD8+ T cells in the DLN correlates with mucosal
T cell adjuvant activity.
4. DISCUSSION
Cell-mediated immune responses play a crucial role in protecting the host from invading
pathogens. Thus, the development of vaccination strategies which are capable of activating
CD8+ T cells possess the potential to significantly influence the outcome of infection with
harmful organisms. Viruses and viral vectors induce potent CD8+ T cell-mediated immunity
in a number of experimental systems, and gaining a mechanistic understanding of both the
immunological and virological basis of T cell activation may in the long run allow for the
optimization of viral vectors as vaccine delivery tools.
Alphavirus expression vectors based on Sindbis virus, Semliki forest virus, and Venezuelan
equine encephalitis virus induce strong CD8+ T cell responses against antigens which are
expressed from the viral genome (reviewed in [5–11]). Under these conditions, all
productively infected cells would also produce heterologous antigen, providing a means for
virally-expressed proteins/peptide fragments to gain access to the MHC class I pathway in
the same cells that receive viral activation signals. Here we demonstrate the ability of VRP,
as an adjuvant, to induce activation of CD8+ T cell responses to a co-delivered antigen. This
is the first formal demonstration of CD8+ T cell adjuvant activity following alphavirus
delivery. Antibody adjuvant activity has been observed with attenuated VEE virus [37, 38]
and with replicon particles derived from VEE [29] and Semliki forest virus [39]; however, T
cell adjuvant effects were either not detected or not examined in those reports.
The mechanism(s) underlying VRP CD8+ T cell adjuvant activity are undefined at present;
however, two general of models are plausible. First, it is possible that T cell activation
results from the interaction of CD8+ T cells with APCs that were both infected by VRP and
had taken up exogenous antigen by phagocytosis and/or pinocytosis. In support of this idea
VRP are known to upregulate co-stimulatory molecule expression on infected mouse
(Moran, T.P., Johnston, R.E., and Serody, J.S., unpublished observations) and human [40]
DC cultures, and promote CD8+ T cell responses to antigens which are encoded in the VRP
genome. Moreover, incubation of peripheral blood mononuclear cells with VRP-infected
DCs in vitro significantly expands antigen-specific CD8+ T cells [40], suggesting that
antigen-bearing, infected cells are sufficient to activate cognate CD8+ T cells.
A second non-mutually exclusive possibility is that, as VRP and OVA may target distinct
APC subsets, VRP may provide an adjuvant signal for CD8+ T cell activation to uninfected,
antigen-bearing APCs, possibly via the secretion of soluble mediators in the DLN.
Consistent with this idea, VRP induce the production of several inflammatory mediators in
the DLN including IFN-β, TNF-α, IL-6, IFN-γ, RANTES, and MIP1-β (Thompson et al., In
Press;[33]) which may affect CD8+ T cell activation. Further experimentation will be
required to determine the relative contributions of both direct activation and cross priming in
the VRP adjuvant system. However, regardless of dependence upon co-delivery of VRP and
antigen to the same cell, we suggest that VRP potentially act downstream of antigen
acquisition and antigen processing, as increased IFN-γ secretion by CD8+ T cells was
observed following delivery of peptide antigen in the presence of VRP. This delivery
circumvents both antigen uptake and processing to the immunogenic peptide Of note in this
regard, VRP delivery alone in the presence of peptide antigen stimulated a significant
adjuvant effect as measured by IFN-γ ELISPOT, whereas only VRP co-delivery with CpG
DNA resulted in an adjuvant effect as measured by pentamer staining (see Fig. 3A and 3B),
which may suggest that VRP adjuvants induce the activation of antigen-specific cells more
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so than the generation antigen-specific cells per se. Further experiments are underway to test
such an hypothesis.
As mentioned above, VRP specifically infect DCs in the lymph node draining the infection
site [30], and preliminary experiments suggest that CD11b+ DCs represent the major target
of VEE infection (West, A., Whitmore, A.C., Moran, T.P., and Johnston, R.E., unpublished
observations). Interestingly, CD11b+ DCs have been implicated in the induction of Th1
CD4+ T cell responses in several model systems [41–43], (reviewed in [26, 44]), raising the
possibility that VRP-infected CD11b+ DCs promote the activation of CD8+ T cell-mediated
immunity by driving helper CD4+ T cells towards a Th1 phenotype in vivo. Consistent with
this idea, both Th1-biased IgG2a antibodies (this report) and Th1 cytokines such as
IL-12p70 and IFN-γ were produced in VRP-infected animals (Thompson et al., In Press;
Thompson, J.M., and Johnston, R.E., unpublished observations). In fact, analysis of the IgG
profile (Fig. 1B) following VRP delivery suggests that VRP adjuvants predominantly
stimulate a Th1-biased IgG2a response. This was a surprising finding, given that VRP also
catalyze Th2 cytokine production such as IL-5 and IL-6 in VRP-infected animals
(Thompson et al., In Press). Nonetheless, such an observation is consistent with an important
role for Th1 CD4+ T cells in VRP CD8+ T cell adjuvant activity, and the importance of the
Th1 phenotype in the VRP adjuvant effect. We are currently evaluating both the role of Th1
CD4+ T cells in the VRP adjuvant effect and the capacity of various subsets of DCs isolated
from the DLN of VRP-infected animals to stimulate co-cultured, antigen-specific CD8+ T
cells, in an attempt to define the mechanisms of T cell activation in the VRP system [45,
46].
Our studies clearly demonstrate that VRP possess intrinsic T cell adjuvant activity; however,
the question of whether our experimental system is optimized for T cell activation has not
been fully addressed. The inoculation regimen utilized in these studies was based upon our
experience utilizing VRP to induce serum IgG responses directed against VRP-expressed
antigens. However, the optimal dosing schedule for the induction of T cell adjuvant activity
may differ from than that for serum antibody responses. We are actively pursuing dosing
schedules and additional methods to further augment the VRP T cell adjuvant effect.
One such method presented here is the utilization of VRP as adjuvants in combination with
the known T cell adjuvant, CpG DNA. Our studies demonstrated stronger T cell adjuvant
effects following co-delivery of both VRP and CpG together, as compared to delivery of
either adjuvant alone. Synergy has been documented following simultaneous delivery of
TLR agonists in terms of either proinflammatory cytokine production or T cell activation
[47–50]. While a direct role for TLR signaling in alphavirus recognition has yet to be fully
clarified, we hypothesized that VRP infection may act synergistically with CpG DNA to
further activate cell mediated immunity. However, increased CD8+ T cell responses
following co-delivery of VRP and CpG DNA in the presence of protein antigen appeared to
be additive as opposed to synergistic. We are currently evaluating the signaling pathways
and cytokine responses activated following delivery of VRP in the presence and absence of
CpG DNA in an attempt to further characterize the mechanism/s of immune induction in this
system. It is possible that VRP- and CpG-induced signaling occurs in distinct temporal
waves, and delivery of VRP and CpG in a different temporal fashion may provide a
synergistic effect. In support of this idea, the kinetics of proinflammatory cytokine
production in the DLN appeared to differ between VRP and CpG DNA, with VRP-induced
responses peaking approximately 18 hours prior to the peak induced by CpG DNA
(Thompson et al., In Press). We are currently evaluating the stimulatory effect of VRP in the
presence of CpG DNA, as well as other TLR ligands, when delivered either simultaneously
or consecutively.
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Nonmucosal VRP delivery resulted in a significant increase in the proportion of CD8+ T
cells in the nasal mucosa, suggesting that VRP infection promotes the mobilization of CD8+
T cells into the mucosal compartment. One possible explanation for this result is that VRP
delivery induces TCR-independent migration of CD8+ T cells into the mucosal
compartment. An alternative explanation is that the increase in mucosal CD8+ T cells in the
mucosal compartment is in fact due to the influx of antigen-specific cells, specific for
antigens other than OVA. While VRP preparations are purified over a sucrose gradient,
“contaminating” proteins present in VRP preparations, or normal antigens cycling through
the VRP-infected lymph node, may be present at levels sufficient for such proteins to serve
as an antigen. VRP may in turn adjuvant the antigen-specific CD8+ T cell response to these
contaminating and/or natural antigens, accounting for CD8+ cell influx into the mucosal
compartment. Additional experiments will be required to distinguish between these
possibilities. Antigen-independent mucosal migration may be evaluated by determining the
ability VRP to induce mucosal migration of adoptively transferred CD8+ T cells with a
specificity distinct from that of the immunizing antigen. Regardless of mechanism, it will be
important to determine whether this property is unique to the nasal mucosa, or if other
mucosal surfaces likewise harbor increased numbers of CD8+ T cells.
Activation of mucosal IgA responses following nonmucosal VRP delivery has also been
observed [29, 51, 52]. Interestingly, IgA antibodies were first produced in the peripheral
draining lymph node, consistent with a model in the DLN plays a role in the inductive
process following nonmucosal VRP delivery (Thompson et al., In Press). Characterization
of the VRP DLN revealed a population of B cells with increased α4β7 integrin expression
and the presence of mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) on the
high endothelial venules, suggesting a role for the mucosal homing receptor interactions in
VRP-induced mucosal antibody activation (Thompson et al., In Press). CD8+ T cells present
in the VRP DLN also upregulated the α4β7integrin, by approximately 3-fold. In this context,
it is of interest that the α4β7 integrin is upregulated on antigen-specific, IFN-γ-secreting
cells both in the DLN and at the vaginal mucosal surface [53] as well as on IgA-secreting
cells in the vaginal mucosal surface [54] following nonmucosal prime and mucosal boost of
an alphavirus replicon chimera containing a VEE replicon RNA, providing additional
support for this pathway in alphavirus replicon-induced mucosal T cell activation. Further
experimentation, such as VRP adjuvant experiments in β7 integrin knock out mice [55], will
be required to definitively implicate of this pathway in VRP-induced mucosal immunity;
however, we speculate that the α4β7 integrin pathway plays a significant role in mucosal
lymphocyte migration in the alphavirus adjuvant system(s).
In summary, we describe for the first time, the ability of VRP to augment CD8+ T cell
responses to co-delivered antigen alone and in concert with a TLR agonist. To our
knowledge, this is the first demonstration of T cell adjuvant activity with alphavirus vectors.
Much of the VRP-induced activation in the presence of CpG DNA appeared to occur
downstream of antigen processing, as increased immunity was observed following delivery
of a peptide antigen. Additionally, VRP delivery resulted in increased homing of CD8+ T
cells into the mucosal compartment, possibly via the mucosal homing receptor. These
studies provide a framework which should allow for the identification of the critical viral
factors and signaling pathways which are responsible for the activation of T cell responses
to co-delivered antigens. In turn, such knowledge could lead to more efficacious vaccines
based on viral vectors.
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Figure 1. VRP adjuvants promote a balanced Th1/Th2 antibody profile
Groups of eight female Balb/c mice were immunized in the rear footpad at week 0 and week
4 with OVA alone (10 μg), or OVA (10 μg) mixed with either null VRP (1×105 IU) or CpG
DNA (1 μg). Two weeks following the second inoculation, sera were collected and analyzed
for the presence of OVA-specific total IgG antibodies (A) or OVA-specific IgG1 and IgG2a
antibodies (B) by ELISA. Values represent the geometric mean ± SEM. *, p<0.001,
compared to OVA alone as determined by ANOVA.
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Figure 2. VRP adjuvants promote an increased cellular immune response to co-delivered soluble
antigen
Groups of eight female C57BL/6 mice were immunized in the rear footpad at week 0 and
week 4 with OVA alone (100 μg), or OVA (100 μg) mixed with either null VRP (1×105
IU), CpG DNA (1 μg), or both null VRP (1×105 IU) and CpG DNA (1 μg). Two weeks
following the second inoculation, splenocytes (A) and nasal lymphocytes (B) were analyzed
for the presence of IFN-γ-secreting cells following stimulation with the OVA class I-
restricted peptide in an IFN-γ ELISPOT assay. Values represent the geometric mean ±
SEM. *, p<0.05; **, p<0.01; **, p<0.001 compared to OVA alone or as indicated, as
determined by ANOVA.
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Figure 3. VRP adjuvants promote an increased cellular immune response to co-delivered peptide
antigen
Groups of eight female C57BL/6 mice were immunized in the rear footpad at weeks 0, 4,
and 8 with OVA peptide (SIINFEKL, 20 μg/20 μg/10 μg respectively) alone, or mixed with
either null VRP (1×105 IU), CpG DNA (1 μg), or both null VRP (1×105 IU) and CpG DNA
(1 μg). Two weeks following the last inoculation, splenocytes (A) were analyzed for the
presence of IFN-γ-secreting cells following stimulation with the OVA class I-restricted
peptide in an IFN-γ ELISPOT assay. Additionally, splenocytes (B) and nasal lymphocytes
(C) were analyzed for the presence pMHC-specific CD8+ T cells by pentamer staining.
Values represent the geometric mean ± SEM. ns, not significant; *, p<0.05; **, p<0.01; ***,
p<0.001 compared to OVA alone or as indicated, as determined by ANOVA.
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Figure 4. Nonmucosal VRP delivery results in increased numbers of mucosal CD8+ T cells
Groups of eight female Balb/c mice were immunized in the rear footpad at weeks 0 and 4
with OVA alone (10 μg), or OVA (10 μg) mixed with null VRP (1×105 IU). Two weeks
following the second inoculation, upper respiratory tract (URT) lymphocytes were evaluated
for the presence of IFN-γ+ CD8+ T cells by ICS following in vitro stimulation with the
OVA class I-restricted peptide (A). Additionally, both the % of CD8+ T cells present in the
URT (B) and the total number of IFN-γ+ CD8+ T cells following peptide stimulation were
also evaluated at two weeks post boost. Values represent the geometric mean ± SEM. ns, not
significant; *, p=0.0286; **, p=0.0002 compared to OVA alone, as determined by Mann-
Whitney.
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Figure 5. VRP upregulate the mucosal homing receptor on DLN CD8+ T cells
Groups of female Balb/c mice were immunized in the rear footpads at weeks 0 and 4 with
OVA alone (10 μg), or mixed with either null VRP (1×105 IU). Day 3 following the last
inoculation, single cell suspensions were prepared from the DLN and CD4+ and CD8+ T
cells were analyzed for the presence of the α4β7 integrin and CCR9 by flow cytometry.
Shown are the proportion of α4β7 integrin positive cells.
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